Comparison of the effect of Ursobil and Silymarine in fatty liver

Comparison of the effect of Ursobil and Silymarine in non alchoholic fatty liver

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016040727265N1

Enrollment

Registered

2016-05-29

Start date

2015-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic steatohepatitis. nonalcoholic steatohepatitis

Interventions

Intervention 1: First group will be received Ursobil (oral capsule

300mg BD for 4 weeks). Intervention 2: Second group will be received Silymarin (oral tablet

140 mg BD for 4 weeks).

Treatment - Drugs

First group will be received Ursobil (oral capsule

300mg BD for 4 weeks)

Second group will be received Silymarin (oral tablet

140 mg BD for 4 weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Confirmation of NAFLD with ultra sonography; increased level of liver enzymes. Exclusion criteria: Alcoholism; hepatotoxic drug users; viral hepatitis and liver metabolic disorder.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Liver enzymes. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: By laboratory analysis ( blood test).;Serum insulin. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Chemiluminescence.;Fasting blood sugar. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: By laboratory analysis ( blood test).;Lipid profile. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: By laboratory analysis ( blood test).;Inflammatory marker. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: By laboratory analysis ( blood test).	—

Measure

Time frame

Liver enzymes. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: By laboratory analysis ( blood test).;Serum insulin. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: Chemiluminescence.;Fasting blood sugar. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: By laboratory analysis ( blood test).;Lipid profile. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: By laboratory analysis ( blood test).;Inflammatory marker. Timepoint: Before intervention and 4 weeks after intervention. Method of measurement: By laboratory analysis ( blood test).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazanin Ghorbanian

Qazvin University of Medical Sciences

nazanin.ghorbanian@yahoo.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026